Latest Information Update: 11 Nov 2002
At a glance
- Originator Nonindustrial source
- Class Antiplatelets
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 27 Mar 2001 Preclinical development for Thrombosis in Belgium (Unknown route)